Di Ruscio Annalisa, de Franciscis Vittorio
Cancer Research Institute, Beth Israel Deaconess Medical Center, 330 Brookline Avenue Boston, Boston, MA 02215, USA.
Harvard Medical School Initiative for RNA Medicine, Harvard Medical School, Boston, MA 02115, USA.
Mol Ther Nucleic Acids. 2022 Aug 6;29:384-386. doi: 10.1016/j.omtn.2022.07.012. eCollection 2022 Sep 13.
Aptamers are RNAs that can bind proteins directly and modulate protein-protein interactions. Given their therapeutic potential, aptamers would be expected to capture the interest of both scientists and investors. However, concerns regarding safety, efficacy, and delivery have delayed aptamer development and dampened investor support. Herein, we discuss the major hurdles stalling the translational application of aptamers over recent years and focus on approaches to overcome current barriers and attract the scientific community and investors to the aptamer field.
适体是能够直接结合蛋白质并调节蛋白质-蛋白质相互作用的RNA。鉴于其治疗潜力，适体有望引起科学家和投资者的兴趣。然而，对安全性、有效性和递送方面的担忧延缓了适体的开发，并削弱了投资者的支持。在此，我们讨论近年来阻碍适体转化应用的主要障碍，并重点关注克服当前障碍以及吸引科学界和投资者进入适体领域的方法。
Zotero 插件